SEC Tracker
Get the app

Bluejay Diagnostics BJDX

Bluejay Diagnostics reports SYMON-II data.

Form
8-K
Filed
Importance
Routine
  1. 777 evaluable patients in SYMON-II study.
  2. 18% 28-day mortality rate.
  3. 39.5% of patients met septic shock criteria.
  4. IL-6 test not yet FDA approved.

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Bluejay Diagnostics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. Interpace Biosciences IDXG public float $3M, Jun 30, 2025
  2. Global Innovative Platforms GIPL public float $3M, Sep 30, 2025
  3. ENDRA Life Sciences NDRA public float $3M, Jun 30, 2025
  4. Stimcell Energetics STME public float $2M, Nov 30, 2025
  5. LogicMark LGMK public float $2M, Jun 30, 2025